Celularity, Inc.
Industry
- Pharmaceuticals
- Biotechnology
- Gene Therapy, Cell Therapy
Other Names/Subsidiaries
- CariCord
- GX Acquisition Corp.
Latest on Celularity, Inc.
Biopharma merger and acquisition value for the fourth quarter of 2024 reached $9.4bn from 34 transactions, 15 of which had disclosed values. At the top was H. Lundbeck’s $2.6bn purchase of publicly tr
Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Novo Nordisk Brings Embark Home After F
The market for initial public offerings by biopharmaceutical companies declined to just 22 IPOs in the US in 2022 and it has gotten off to a slow start in 2023 with just three small offerings to date,
Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Cidara Hopes For Early 2023 Approval Of